Merck & Company, Inc. (NYSE:MRK) – Investment analysts at Leerink Swann raised their Q3 2017 EPS estimates for Merck & in a report issued on Monday. Leerink Swann analyst S. Fernandez now anticipates that the company will post earnings of $1.03 per share for the quarter, up from their previous forecast of $0.99. Leerink Swann has a “Market Perform” rating and a $70.00 price target on the stock. Leerink Swann also issued estimates for Merck &’s FY2018 earnings at $3.99 EPS and FY2019 earnings at $4.23 EPS.

Several other equities research analysts have also commented on the stock. Jefferies Group LLC reaffirmed a “sell” rating and set a $52.00 price target on shares of Merck & in a research report on Sunday, August 20th. BMO Capital Markets reaffirmed a “buy” rating and set a $72.00 price target on shares of Merck & in a research report on Friday, September 8th. Credit Suisse Group reduced their price target on shares of Merck & from $75.00 to $74.00 and set an “outperform” rating for the company in a research report on Wednesday, August 30th. BidaskClub lowered shares of Merck & from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, Cowen and Company reaffirmed a “hold” rating and set a $70.00 price target on shares of Merck & in a research report on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $70.67.

TRADEMARK VIOLATION WARNING: “Leerink Swann Weighs in on Merck & Company, Inc.’s Q3 2017 Earnings (MRK)” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/25/leerink-swann-weighs-in-on-merck-company-inc-s-q3-2017-earnings-mrk.html.

Merck & (MRK) opened at 63.11 on Wednesday. Merck & has a 12 month low of $58.29 and a 12 month high of $66.80. The firm’s 50-day moving average is $64.51 and its 200-day moving average is $63.71. The company has a market cap of $172.12 billion, a price-to-earnings ratio of 34.17 and a beta of 0.80.

Merck & (NYSE:MRK) last issued its earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.87 by $0.14. The firm had revenue of $9.93 billion during the quarter, compared to analyst estimates of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The company’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter last year, the business earned $0.93 earnings per share.

A number of hedge funds have recently bought and sold shares of the business. Davis R M Inc. boosted its stake in Merck & by 4.3% in the 3rd quarter. Davis R M Inc. now owns 266,011 shares of the company’s stock worth $17,033,000 after purchasing an additional 10,903 shares during the period. TIAA FSB boosted its stake in Merck & by 4.8% in the 3rd quarter. TIAA FSB now owns 295,447 shares of the company’s stock worth $18,917,000 after purchasing an additional 13,406 shares during the period. First Trust Advisors LP boosted its stake in Merck & by 16.7% in the 3rd quarter. First Trust Advisors LP now owns 394,341 shares of the company’s stock worth $25,250,000 after purchasing an additional 56,289 shares during the period. OLD Point Trust & Financial Services N A boosted its stake in Merck & by 10.8% in the 3rd quarter. OLD Point Trust & Financial Services N A now owns 34,349 shares of the company’s stock worth $2,199,000 after purchasing an additional 3,350 shares during the period. Finally, Sky Investment Group LLC boosted its stake in Merck & by 2.0% in the 3rd quarter. Sky Investment Group LLC now owns 66,840 shares of the company’s stock worth $4,280,000 after purchasing an additional 1,285 shares during the period. Institutional investors and hedge funds own 72.86% of the company’s stock.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Earnings History and Estimates for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.